Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 1,300 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $80.03, for a total value of $104,039.00. Following the transaction, the insider now owns 143,276 shares of the company’s stock, valued at approximately $11,466,378.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Haig P. Bozigian also recently made the following trade(s):

  • On Monday, May 13th, Haig P. Bozigian sold 34,547 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $75.51, for a total value of $2,608,643.97.

Shares of NBIX traded down $1.04 during trading hours on Thursday, reaching $78.75. 547,800 shares of the company traded hands, compared to its average volume of 947,659. The firm has a market capitalization of $7.28 billion, a price-to-earnings ratio of 357.95 and a beta of 1.73. The company has a current ratio of 8.79, a quick ratio of 8.61 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences, Inc. has a 12 month low of $64.72 and a 12 month high of $126.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, April 29th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). The company had revenue of $138.40 million for the quarter, compared to the consensus estimate of $136.77 million. Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The company’s revenue for the quarter was up 94.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.47) EPS. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post -0.24 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank purchased a new position in Neurocrine Biosciences during the 4th quarter valued at about $61,171,000. Orbimed Advisors LLC lifted its position in Neurocrine Biosciences by 258.6% during the 4th quarter. Orbimed Advisors LLC now owns 494,200 shares of the company’s stock valued at $35,291,000 after acquiring an additional 356,400 shares during the period. Thrivent Financial for Lutherans lifted its position in Neurocrine Biosciences by 94.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 691,851 shares of the company’s stock valued at $49,405,000 after acquiring an additional 336,101 shares during the period. First Trust Advisors LP lifted its position in Neurocrine Biosciences by 27.3% during the 4th quarter. First Trust Advisors LP now owns 1,299,455 shares of the company’s stock valued at $92,794,000 after acquiring an additional 278,598 shares during the period. Finally, Marshall Wace North America L.P. lifted its position in Neurocrine Biosciences by 83.5% during the 1st quarter. Marshall Wace North America L.P. now owns 580,904 shares of the company’s stock valued at $51,178,000 after acquiring an additional 264,402 shares during the period.

Several equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating and set a $105.00 price objective for the company in a research report on Wednesday, April 10th. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Credit Suisse Group started coverage on shares of Neurocrine Biosciences in a report on Monday. They issued an “outperform” rating and a $95.00 target price on the stock. Barclays restated a “buy” rating and issued a $110.00 target price on shares of Neurocrine Biosciences in a report on Friday, March 29th. Finally, Evercore ISI initiated coverage on shares of Neurocrine Biosciences in a research report on Thursday, April 11th. They issued an “outperform” rating for the company. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $102.95.

ILLEGAL ACTIVITY NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Insider Sells $104,039.00 in Stock” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-insider-sells-104039-00-in-stock/3020193.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: Beige Book

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.